Miriam Gaggianesi

Dr. Miriam Gaggianesi

Department of Surgical, Oncological and Oral Sciences (Di.Chir.On.S.)
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Cell Stem Cell
Verified
Journal Article
Closed access
MTMatilde Todaro
Matilde Todaro
Miriam GaggianesiMiriam Gaggianesi
Miriam Gaggianesi
VCVeronica Catalano
Veronica Catalano
ABAntonina Benfante
Antonina Benfante
FIFlora Iovino
Flora Iovino
GSGiorgio Stassi
Giorgio Stassi

18 February 2019 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
ATAlice Turdo
Alice Turdo
Veronica VeschiVeronica Veschi
Veronica Veschi
Miriam GaggianesiMiriam Gaggianesi
Miriam Gaggianesi
ACAurora Chinnici
Aurora Chinnici
PBPaola Bianca
Paola Bianca
GSGiorgio Stassi
Giorgio Stassi
Notwithstanding cancer patients benefit from a plethora of therapeutic alternatives, drug resistance remains a critical hurdle. Indeed, the high mortality rate is associated with metastatic disease, which is mostly incurable due to the refractoriness of metastatic cells to current treatments. Increasing data demonstrate that tumors contain a small subpopulation of cancer stem cells (CSCs) able to establish primary tumor and metastasis. CSCs are endowed with multiple treatment resistance capabilities comprising a highly efficient DNA damage repair machinery, the activation of survival pathways, enhanced cellular plasticity, immune evasion and the adaptation to a hostile microenvironment. Due to the presence of distinct cell populations within a tumor, cancer research has to face the major challenge of targeting the intra-tumoral as well as inter-tumoral heterogeneity. Thus, targeting molecular drivers operating in CSCs, in combination with standard treatments, may improve cancer patients’ outcomes, yielding long-lasting responses. Here, we report a comprehensive overview on the most significant therapeutic advances that have changed the known paradigms of cancer treatment with a particular emphasis on newly developed compounds that selectively affect the CSC population. Specifically, we are focusing on innovative therapeutic approaches including differentiation therapy, anti-angiogenic compounds, immunotherapy and inhibition of epigenetic enzymes and microenvironmental cues.

19 October 2015 in Oncotarget
Verified
Journal Article
Open access
GRGiuseppina Roscigno
Giuseppina Roscigno
CQCristina Quintavalle
Cristina Quintavalle
EDElvira Donnarumma
Elvira Donnarumma
IPIlaria Puoti
Ilaria Puoti
ADAngel Diaz-Lagares
Angel Diaz-Lagares
Gerolama CondorelliGerolama Condorelli
Gerolama Condorelli
MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b

18 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
Simone Di FrancoSimone Di Franco
Simone Di Franco
PBPaola Bianca
Paola Bianca
DSDavide Stefano Sardina
Davide Stefano Sardina
ATAlice Turdo
Alice Turdo
Miriam GaggianesiMiriam Gaggianesi
Miriam Gaggianesi
GSGiorgio Stassi
Giorgio Stassi
Obesity is a strong risk factor for cancer progression, posing obesity-related cancer as one of the leading causes of death. Nevertheless, the molecular mechanisms that endow cancer cells with metastatic properties in patients affected by obesity remain unexplored.Here, we show that IL-6 and HGF, secreted by tumor neighboring visceral adipose stromal cells (V-ASCs), expand the metastatic colorectal (CR) cancer cell compartment (CD44v6 + ), which in turn secretes neurotrophins such as NGF and NT-3, and recruits adipose stem cells within tumor mass. Visceral adipose-derived factors promote vasculogenesis and the onset of metastatic dissemination by activation of STAT3, which inhibits miR-200a and enhances ZEB2 expression, effectively reprogramming CRC cells into a highly metastatic phenotype. Notably, obesity-associated tumor microenvironment provokes a transition in the transcriptomic expression profile of cells derived from the epithelial consensus molecular subtype (CMS2) CRC patients towards a mesenchymal subtype (CMS4). STAT3 pathway inhibition reduces ZEB2 expression and abrogates the metastatic growth sustained by adipose-released proteins. Together, our data suggest that targeting adipose factors in colorectal cancer patients with obesity may represent a therapeutic strategy for preventing metastatic disease.

14 June 2017 in Cancer Research
Verified
Journal Article
Open access
PDF file
Miriam GaggianesiMiriam Gaggianesi
Miriam Gaggianesi
ATAlice Turdo
Alice Turdo
ACAurora Chinnici
Aurora Chinnici
ELElisa Lipari
Elisa Lipari
TATiziana Apuzzo
Tiziana Apuzzo
MTMatilde Todaro
Matilde Todaro
The tumor microenvironment supplies proinflammatory cytokines favoring a permissive milieu for cancer cell growth and invasive behavior. Here we show how breast cancer progression is facilitated by IL4 secreted by adipose tissue and estrogen receptor–positive and triple-negative breast cancer cell types. Blocking autocrine and paracrine IL4 signaling with the IL4Rα antagonist IL4DM compromised breast cancer cell proliferation, invasion, and tumor growth by downregulating MAPK pathway activity. IL4DM reduced numbers of CD44+/CD24− cancer stem-like cells and elevated expression of the dual specificity phosphatase DUSP4 by inhibiting NF-κB. Enforced expression of DUSP4 drove conversion of metastatic cells to nonmetastatic cells. Mechanistically, RNAi-mediated attenuation of DUSP4 activated the ERK and p38 MAPK pathways, increased stem-like properties, and spawned metastatic capacity. Targeting IL4 signaling sensitized breast cancer cells to anticancer therapy and strengthened immune responses by enhancing the number of IFNγ-positive CTLs. Our results showed the role of IL4 in promoting breast cancer aggressiveness and how its targeting may improve the efficacy of current therapies. Cancer Res; 77(12); 3268–79. ©2017 AACR.

1 June 2021 in iScience
Verified
Journal Article
Open access
Simone Di FrancoSimone Di Franco
Simone Di Franco
BPBarbara Parrino
Barbara Parrino
Miriam GaggianesiMiriam Gaggianesi
Miriam Gaggianesi
VPVincenzo Davide Pantina
Vincenzo Davide Pantina
PBPaola Bianca
Paola Bianca
GSGiorgio Stassi
Giorgio Stassi
Limited therapeutic options are available for advanced colorectal cancer (CRC). Herein, we report that exposure to a neo-synthetic bis(indolyl)thiazole alkaloid analog, nortopsentin 234 (NORA234), leads to an initial reduction of proliferative and clonogenic potential of CRC sphere cells (CR-CSphCs), followed by an adaptive response selecting the CR-CSphC-resistant compartment. Cells spared by the treatment with NORA234 express high levels of CD44v6, associated with a constitutive activation of Wnt pathway. In CR-CSphC-based organoids, NORA234 causes a genotoxic stress paralleled by G2-M cell cycle arrest and activation of CHK1, driving the DNA damage repair of CR-CSphCs, regardless of the mutational background, microsatellite stability, and consensus molecular subtype. Synergistic combination of NORA234 and CHK1 (rabusertib) targeting is synthetic lethal inducing death of both CD44v6-negative and CD44v6-positive CRC stem cell fractions, aside from Wnt pathway activity. These data could provide a rational basis to develop an effective strategy for the treatment of patients with CRC.